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Abstract
Background Breast cancer patients report a perception of increased muscle fatigue, which can persist following surgery and
standardized therapies. In a clinical experiment, we tested the hypothesis that pathways regulating skeletal muscle fatigue are
down-regulated in skeletal muscle of breast cancer patients and that different muscle gene expression patterns exist between
breast tumour subtypes. In a preclinical study, we tested the hypothesis that mammary tumour growth in mice induces
skeletal muscle fatigue and that overexpression of the cytokine interleukin-15 (IL-15) can attenuate mammary tumour-
induced muscle fatigue.
Methods Early stage non-metastatic female breast cancer patients (n = 14) and female non-cancer patients (n = 6) provided a
muscle biopsy of the pectoralis major muscle during mastectomy, lumpectomy, or breast reconstruction surgeries. The breast
cancer patients were diagnosed with either luminal (ER+/PR+, n = 6), triple positive (ER+/PR+/Her2/neu+, n = 5), or triple negative
(ER/PR/Her2/neu, n = 3) breast tumours and were being treated with curative intent either with neoadjuvant chemother-
apy followed by surgery or surgery followed by standard post-operative therapy. Biopsies were used for RNA-sequencing to
compare the skeletal muscle gene expression patterns between breast cancer patients and non-cancer patients. The
C57BL/6 mouse syngeneic mammary tumour cell line, E0771, was used to induce mammary tumours in immunocompetent
mice, and isometric muscle contractile properties and fatigue properties were analysed following 4 weeks of tumour growth.
Results RNA-sequencing and subsequent bioinformatics analyses revealed a dysregulation of canonical pathways involved in
oxidative phosphorylation, mitochondrial dysfunction, peroxisome proliferator-activated receptor signalling and activation,
and IL-15 signalling and production. In a preclinical mouse model of breast cancer, the rate of muscle fatigue was greater in
mice exposed to mammary tumour growth for 4 weeks, and this greater muscle fatigue was attenuated in transgenic mice
that overexpressed the cytokine IL-15.
Conclusions Our data identify novel genes and pathways dysregulated in the muscles of breast cancer patients with early
stage non-metastatic disease, with particularly aberrant expression among genes that would predispose these patients to
greater muscle fatigue. Furthermore, we demonstrate that IL-15 overexpression can attenuate muscle fatigue associated with
mammary tumour growth in a preclinical mouse model of breast cancer. Therefore, we propose that skeletal muscle fatigue is
an inherent consequence of breast tumour growth, and this greater fatigue can be targeted therapeutically.
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Introduction
The concepts of muscle wasting and functional muscle
impairment (i.e. fatigue) are included in the definition of
cachexia.1,2 The underlying mechanisms that can promote
muscle wasting are not necessarily the same as those that
can promote muscle fatigue,3 and patients may experience
muscle fatigue without significant loss of skeletal muscle
mass.4 Although a relatively small percentage of patients
with breast cancer demonstrates evidence of body weight
loss5 and reduced skeletal muscle strength,6,7 a large percent-
age of breast cancer patients reports moderate to severe
fatigue, which can be exacerbated during radiation therapy
and chemotherapy3,8–10 and can last for years after cancer
treatments conclude.8,9 Notably, one study reported that up
to 99% of patients with breast cancer report some degree
of fatigue.11 While both central and peripheral mechanisms
of fatigue have been hypothesized to contribute to overall
fatigue in cancer patients,12 breast cancer patients were able
to improve muscle fatigue, strength, and lean body mass in
response to structured exercise programmes suggesting
peripheral mechanisms of fatigue can be improved in these
patients.13,14 The fact that fatigue is reported in such a high
percentage of breast cancer patients suggests that the molec-
ular alterations within skeletal muscle may initially predis-
pose these patients to fatigue and not necessarily muscle
mass loss. Therefore, knowledge of the molecular alterations
of skeletal muscle during breast cancer is required to design
interventions targeting muscle fatigue in this group of
patients, which would theoretically affect patient mobility
and quality of life.
The cytokine interleukin-15 (IL-15) has shown promise as
an immunotherapy in early phase clinical trials in cancer
patients.15 IL-15 is critical for the maintenance of NK cell
and CD8 T cell number and function (see reviews Waldmann
and Tagaya16 and Fehniger and Caligiuri17). Our laboratory
and others have shown that IL-15 is also associated with
enhancing the oxidative capacity of skeletal muscle.18–22
Specifically, mice genetically modified to have greater circu-
lating levels of IL-15 have a greater mitochondrial density in
skeletal muscle, a greater resistance to contraction induced
fatigue, and can perform longer on a motorized tread-
mill.18,20,23 Data from our laboratory and others support a
direct effect of IL-15 on skeletal muscle cells, as myotubes
incubated with recombinant IL-15 show dose-dependent
increases in gene expression for regulators of mitochondrial
biogenesis, as well as greater mitochondrial density.19,24
These data have been supported by studies in mice, in which
IL-15 promotes the expression of peroxisome proliferator-
activated receptor delta (PPARδ), PPARβ, and peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1α) in muscle.20 Therefore, IL-15 may represent a sup-
portive therapy for cancer patients with dual roles: enhancing
immune system surveillance and attenuating muscle fatigue.
The purpose of this study was to characterize skeletal
muscle gene expression patterns and regulatory networks in
response to breast cancer and utilize bioinformatics to
predict dysregulated pathways in muscle from breast cancer
patients compared with muscle from non-cancer patients.
We tested the hypotheses that pathways regulating skeletal
muscle fatigue are down-regulated in muscle biopsies from
breast cancer patients and that differential gene expression
patterns exist between breast tumour subtypes. In partial
support of this hypothesis, canonical pathways involved in
oxidative phosphorylation, mitochondrial dysfunction, PPAR
activation and signalling, and IL-15 signalling and production
were dysregulated in muscle from all breast cancer patients
in our study compared with non-cancer controls. However,
we observed no differences in the skeletal muscle tran-
scriptome between patients with three different breast
tumour subtypes (i.e. luminal; triple positive; triple negative).
In a subsequent preclinical mouse study, muscle fatigue that
occurred in response to 4 weeks of mammary tumour growth
was attenuated in transgenic mice that overexpressed IL-15.
Collectively, our data identify novel genes and pathways that
are dysregulated in the muscle of breast cancer patients and
provide significant support for the use of IL-15-based thera-
pies to attenuate muscle fatigue associated with mammary
tumour growth, regardless of the tumour molecular subtype.
Materials and methods
Muscle biopsies from breast cancer patients
The Institutional Review Board at West Virginia University
approved all procedures, and eligible patients provided
written consent for participation. Body mass, height, breast
tumour type, oestrogen receptor (ER) percentage, progester-
one receptor (PR) percentage, Her2/neu percentage, and any
cancer-related treatments were obtained from a prospective
chart review. Muscle biopsies from the pectoralis major
skeletal muscle of breast cancer patients (n = 14) were ob-
tained at the time of mastectomy or lumpectomy surgeries.
Approximately 75 mg of tissue was obtained from the muscle
directly under the portion of the affected breast. Pectoralis
major muscle biopsies from control patients were obtained
from either patients with BRCA gene mutations without diag-
nosed cancer that were undergoing prophylactic mastectomy
(n = 3) or women undergoing breast reconstruction surgery
(n = 3). Biopsies were stored in RNA stabilization solution
overnight at 4°C and then transferred to 80°C for storage.
RNA isolation, sequencing, and bioinformatics
Total RNA was isolated from muscle biopsies using Trizol and
established methods.25 Libraries were constructed from
702 J. Bohlen et al.
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 701–714
DOI: 10.1002/jcsm.12294
500 ng of total RNA using a stranded mRNA-Seq kit (KAPA Bio-
sciences,Wilmington, MA, USA). The concentration of each in-
dividual library was quantified with a Qubit fluorometer
(Invitrogen, Carlsbad, CA, USA), and an estimate of size was de-
termined using an Agilent Bioanalyzer with a High Sensitivity
DNA chip (Agilent Genomics, Santa Clara, CA, USA). The librar-
ies were pooled at an equimolar ratio and sequenced using a
HiSeq 2500 sequencing system (Illumina, San Diego, CA, USA).
Read quality was assessed using FastQC (http://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc/). The sequence reads
weremapped to hg38 using STAR26 and then genes were quan-
tified using featureCounts.27 Differential gene expression was
analysed using DESeq2.28 Gene enrichment analysis was per-
formed using GAGE29 against KEGG pathways and the Canoni-
cal Pathways feature of Ingenuity Pathway Analysis (IPA).
Experimental mice
Female C57BL/6 mice (stock #: 000664) were purchased from
The Jackson Laboratory at 12 weeks of age (n = 30) and ran-
domly assigned to three groups: control mice (Con; n = 8),
mice that were euthanized following 2 weeks of tumour
growth (2WK, n = 5) and mice that were euthanized following
4 weeks of tumour growth (4WK, n = 17). Muscle-specific IL-
15 overexpressing transgenic mice (IL15TG) on a C57BL/6
background (stock #: 011002) were purchased from The
Jackson Laboratory to establish a breeding colony. These
transgenic mice overexpress a secretable form of IL-15 within
skeletal muscle, which results in greater circulating levels of
this cytokine.30 Female IL15TG (n = 19) and B6 littermate
control (B6 Con; n = 25) mice were used for studies between
14 and 16 weeks of age and were randomly assigned to the
following groups: B6 Con (n = 8); B6 Con Tumour (n = 17);
IL15TG (n = 7); and IL15TG Tumour (n = 12). Mice were
exposed to mammary tumour growth for 4 weeks, as de-
scribed in the succeeding texts. Mice were housed in the
animal vivarium at West Virginia University in an ABSL-2 level
room following tumour cell implantation, at 22°C under a
12:12-h light–dark cycle and received food and water ab
libitum. The Institutional Animal Care and Use Committee at
West Virginia University approved all animal experiments.
E0771 murine breast cancer cells
The E0771 murine mammary tumour cell line is a syngeneic
medullary adenocarcinoma originally isolated from a
spontaneous tumour in C57BL/6 mice.31–33 The cell line used
in these studies expressed the luciferase enzyme, which
allowed for in vivo tumour imaging after luciferin injection.
E0771 cells were cultured using aseptic technique and
maintained under standard mammalian culture conditions
(37°C, 99% humidity, 5% CO2). Cells were maintained in high
glucose Dulbecco’s modified Eagle’s medium supplemented
with 10% foetal bovine serum to maintain active prolifera-
tion. Cells were passed via trypsinization using 0.25%
trypsin/ethylenediaminetetraacetic acid in Hanks buffered
saline solution. For cell implantation, 1 × 106 E0771 cells
were suspended in sterile phosphate buffered saline and
orthotopically implanted into the mammary fat pad adjacent
to the 4th nipple on the left side of experimental mice. E0771
cells were screened for the presence of contaminants prior to
use (IDEXX Bioresearch).
In vivo tumour bioluminescence and volume
measurements
Bioluminescent imaging of E0771 tumour cells in vivo
was performed weekly following tumour cell implantation,
using an IVIS Lumina II system. Mice were weighed, and
150-mg kg1 D-luciferin substrate was injected into the peri-
toneal cavity. Mice were anaesthetized by inhalation of
isoflurane (3% to induce; 1.5% to maintain anaesthesia),
and in vivo images were acquired and analysed using Living
Image software. The luciferase activity (photons s1) was
quantified and used to ensure progressive tumour growth
and continued cell viability. Tumour volume was quantified
using hand-held callipers and the following formula: length
(mm) × width2 (mm) × 0.5236.
Ex vivo muscle physiological analysis
Ex vivo muscle contractile properties were examined in
the fast extensor digitorum longus (EDL) muscles of experi-
mental mice using a commercially available muscle
physiology system (Aurora Scientific, Ontario, Canada) as pre-
viously described.18,34,35 All experiments were performed in
oxygenated Ringer’s solution (100 mM NaCl, 4.7 mM KCl,
3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM
HEPES, and 5.5 mM D-glucose) that was maintained at 22°C
using a circulating water bath. Muscle length was adjusted
to optimal length (Lo) based on the maximal twitch response.
The force–frequency relationship was generated by stimulat-
ing muscles with increasing frequencies as follows: 1, 5, 10,
25, 50, 80, 100, 120, and 150 Hz. Muscle fatigue was analysed
using a repeated stimulation protocol lasting 6 min and
consisting of repeated 40-Hz tetanic trains that occurred once
every second and lasted 330 ms. The fatigue index was calcu-
lated as the per cent difference in force of each contraction
from the initial contraction of the protocol and plotted as a
fatigue curve.18,36 LabChart software V7 (ADInstruments, Col-
orado Springs, CO, USA) was used to obtain the area under
the fatigue curve (AUC) for each skeletal muscle analysed
and used as a measure of total force production during the
fatigue protocol. There were no differences in contractile
Skeletal muscle transcriptome of breast cancer patients 703
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properties when comparing muscles from the left and the
right limb, so all muscles were combined for final analyses
(data not shown).
Il15 gene expression analysis in skeletal muscle
Total RNA was isolated from the tibialis anterior skeletal
muscles of experimental mice using Trizol reagent (Life Tech-
nologies, Grand Island, NY, USA), as previously described.25
RNA quantity and quality were assessed using a Nano-Drop
2000 spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA); the 260/280 ratio for all samples used was
between 1.8 and 2.1. Two micrograms of total RNA was
reverse transcribed to make cDNA using a high-capacity
reverse transcription kit according to manufacturer’s instruc-
tions (Life Technologies). Primers for murine Il15 were
(forward) 50-TCTTCATGGTCCTTGCTGGT; (reverse) 50-GGCCTC
TGTTTTAGGGAGACC. Amplification was performed using a
solution consisting of 8.5 μL nuclease free H2O, 12.5 μL 2×
Taq-Pro Red Complete 1.5 mM MgCl2 master mix (Denville
Scientific, Metuchen, NJ, USA), 1.0 μL forward primer,
1.0 μL reverse primer, and 2 μL of DNA template to make a
25-μL total reaction volume. Primer pairs for IL-15 were co-
amplified with primer pairs for 18S (Ambion, Austin, TX, USA).
The number of PCR cycles was determined in preliminary ex-
periments to ensure that analyses were performed in the linear
range of amplification. Following amplification, each reaction
was visualized following gel electrophoresis in 1.5% (w/v) aga-
rose gels stained with ethidium bromide. PCR bands were
quantified using the Image J software program (http://
rsbweb.nih.gov/ij/). Signals for the Il15 gene were normalized
to the bands for 18S that were amplified in the same reaction.
Statistical analyses
All data were analysed using the GraphPad Prism 5.0 statisti-
cal software package (Graph Pad Software, La Jolla, CA, USA).
Descriptive statistics were used to summarize the data, in-
cluding mean ± standard deviation for continuous variables.
All descriptive data and muscle contractile data were
analysed using t-test, one-way analysis of variance, or two-
way analysis of variance with Tukey’s post-hoc test, where
appropriate. The null hypothesis was rejected when P< 0.05.
Results
Patient characteristics
Patient characteristics are presented in Table 1. A total of 14
female breast cancer patients and 6 female non-cancer pa-
tients were recruited for the study. There were no differences
in age between the two groups (breast cancer: 56.5y ± 17.2;
control: 44.2y ± 7.4; P = 0.1105). The sample of breast cancer
patients included those diagnosed with luminal tumours
(ER+/PR+; n = 6), triple positive tumours (ER+/PR+/Her2/
neu+; n = 5), and triple negative tumours (n = 3); none of
the breast cancer patients were diagnosed with metastatic
disease. Six breast cancer patients received neoadjuvant
chemotherapy prior to surgery and biopsy acquisition, while
the remaining eight breast cancer patients received adjuvant
chemotherapy following surgery and biopsy acquisition.
Breast cancer patients had an average serum albumin of
3.7 ± 0.3 g dL1, which is within the normal range. Breast
cancer patients had an average body mass index (BMI) of
29.9 ± 10.5 kg m2, which is considered overweight. Non-
cancer patients had an average BMI of 32.3 ± 9.1 kg m2,
which is considered class I obesity. There were no differences
in BMI between groups (P = 0.6396).
Transcriptional alterations in skeletal muscle of
breast cancer patients
Total RNA was isolated from muscle biopsies and used to gen-
erate comparative gene expression profiles of skeletal muscle
in breast cancer patients compared with non-cancer patients.
Principle components analysis allowed us to visualize the vari-
ability of all biopsies and revealed that the 14 biopsies from
breast cancer patients clustered together, regardless of the tu-
mour subtype. In contrast, the six biopsies from non-cancer pa-
tients were considerably separated, with two biopsies
clustering closely with the breast cancer patients. The biopsies
from non-cancer patients did not cluster based on those with
BRCA gene mutations or those that had breast reconstruction
surgery (Figure 1A). Based on this principle components analy-
sis plot, the biopsies from breast cancer patients were analysed
as one group, instead of separating them based on tumour sub-
type. Figure 1B shows a gene expression heat map for all biop-
sies based on the normalized expression of the 40 most
differentially expressed genes. Compared with non-cancer pa-
tients, there was a general down-regulation of genes in the bi-
opsies from breast cancer patients.
RNA-seq data were analysed using both IPA and GAGE
pathway algorithms. Using GAGE software, the following
KEGG pathways were the most down-regulated in the
muscles of breast cancer patients: ribosome (hsa03010; False
Discovery Rate (FDR) = 3.02e12); phagosome (hsa04145;
FDR = 4.90e05); oxidative phosphorylation (hsa00190;
FDR = 3.83e04); proteasome (hsa03050; FDR = 0.010); and
PPAR signalling pathway (hsa03320; FDR = 0.031). The
ubiquitin-mediated proteolysis pathway was up-regulated in
this dataset (hsa04120; FDR = 6.81e03). Table 2 presents
the significantly dysregulated genes, identified using IPA,
within the canonical pathways of oxidative phosphorylation,
mitochondrial dysfunction, and PPAR activation and
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signalling. A total of nine genes were significantly down-
regulated within the oxidative phosphorylation and mito-
chondrial dysfunction category. Multiple genes within Com-
plex I (NADH:ubiquinone), Complex IV (cytochrome c
oxidase), and Complex V [adenosine triphosphate (ATP) syn-
thase] of the mitochondrial electron transport chain (ETC)
were down-regulated (Figure 2). Additionally, antioxidant
genes (gpx4; sod3) were down-regulated in muscle of breast
cancer patients. Within the PPAR activation and signalling
pathway, there were eight down-regulated genes and eight
up-regulated genes (Table 2). Notably, the algorithm pre-
dicted a down-regulation of a gene network that would be
associated with an impairment of β-oxidation within the mi-
tochondria. Specifically, genes involved in energy
homoeostasis and mitochondrial metabolism that were dys-
regulated in muscle of breast cancer patients include pparg,
ppara, ppargc1a, foxo1, fasn, esr1, and cebpa. Genes associ-
ated with alterations in muscle differentiation and stem cell
function, including klf4, ep300, prmt5, and srebf1 were also
included in this gene network (Figure 3). Based on these gene
alterations, we investigated if genes within the IL-15 signal-
ling and production canonical pathways were dysregulated.
There were two down-regulated genes and five up-regulated
genes, consistent with dysregulation of IL-15 signalling
and/or production (Table 2). Collectively, these data suggest
that the muscle fatigue experienced by breast cancer patients
may be at least partially attributable to dysregulation of the
canonical pathways involved in oxidative phosphorylation,
mitochondrial dysfunction, PPAR signalling, and IL-15
signalling.
Skeletal muscle dysfunction in wild type mice in
response to E0771 mammary tumours
We utilized a mouse syngeneic breast tumour cell line to
determine whether mammary tumour growth directly
contributes to skeletal muscle fatigue. Following cell im-
plantation, in vivo bioluminescence, based on luciferase en-
zyme activity, and tumour volume were monitored weekly.
As seen in Figure 4A, tumour size and tumour cell viability
progressively increased through 4 weeks. Bioluminescence,
quantified as total flux, peaked at the end of week 4
(Figure 4B). Tumour volume averaged 397.3 ± 75.5 mm3 after
2 weeks and 3816.5 ± 2987.6 mm3 after 4 weeks of tumour
growth. Bioluminescent analysis also demonstrated positive
metastases in the lungs of mice starting at 2 weeks after
tumour cell implantation (data not shown). Tumour growth
Table 1 Patient characteristics



















BC-1 Luminal 100 99 1 1, 0, 0 None 74 NA 72.7 31.5
BC-2 Luminal 100 100 2 (FISH ) 2, 0, 0 None 46 3.7 70.0 25.7
BC-3 Luminal 100 100 1 2, 1, 0 None 40 3.6 72.3 25.9
BC-4 Luminal 100 98 1 1c, 0, 0 None 86 NA 81.4 28.1
BC-5 Luminal 80 100 1 2, 0, 0 None 73 3.6 85.9 33.6
BC-6 Luminal 100 16 1 2, 0, 0 Chemotherapy 42 3.7 85.0 31.6
BC-7 ER+/PR+/
Her2/neu+
80 80 2 (FISH +) 2, 0, 0 Chemotherapy 31 3.6 67.7 26.5
BC-8 ER+/PR+/
Her2/neu+
100 50 3 1, 0, 0 None 54 4.1 79.5 33.1
BC-9 ER+/PR+/
Her2/neu+
100 100 2 (FISH +) 2, 0, 0 Chemotherapy 69 3.1 168.2 63.6
BC-10 ER+/PR+/
Her2/neu+
100 97 3 1, 0, 0 None 29 3.8 67.7 23.1
BC-11 ER+/PR+/
Her2/neu+
100 0 3 1, 0, 0 None 68 4.3 67.3 24.7
BC-12 Triple
negative/basal
0 0 0 2, 0, 0 Chemotherapy 66 3.5 77.7 28.9
BC-13 Triple
negative/basal
0 0 1 (FISH ) 2, 0, 0 Chemotherapy 60 3.8 46.4 20.5
BC-14 Triple
negative/basal
0 0 0 4, 2, 0 Chemotherapy 54 3.8 64.1 21.4
CON-1 Control (BRCA1) 34 NA 65.0 22.4
CON-2 Control (BRCA2) 40 NA 74.5 26.1
CON-3 Control (BRCA2) 44 NA 89.5 33.9
CON-4 Control 48 3.9 65.0 25.4
CON-5 Control 56 NA 109.5 41.4
CON-6 Control 43 4.0 110.0 44.2
BC, breast cancer; BMI, body mass index; CON, control mice; ER, oestrogen receptor; PR, progesterone receptor.
The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of me-
tastasis (M). It is a clinical staging system used to describe tumors.
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was associated with a progressive loss of overall body mass
(Figure 4C) and individual skeletal muscle mass (Table 3).
Gene expression for il15 within skeletal muscle of
tumour-bearing mice declined in response to tumour
growth, with the lowest il15 gene expression observed in
muscles from mice after 4 weeks of tumour growth (Figure
4D). Ex vivo skeletal muscle stimulation revealed a greater
rate of muscle fatigue upon repeated contraction in mus-
cles from mice after 4 weeks of tumour growth compared
with muscles from control mice and mice after 2 weeks
of tumour growth (Figure 4E). The AUC, representative of
the total amount of contractile force produced during the
fatigue protocol, was also significantly lower in muscles
from mice after 4 weeks of tumour growth compared with
muscles from control mice (Figure 4F). Maximal isometric
force production was significantly lower in muscles from
mice after 4 weeks of tumour growth compared with mus-
cles from control mice and mice after 2 weeks of tumour
growth (Figure 4G). Collectively, these data demonstrate
that E0771 mammary tumour growth contributes to signif-
icant reductions in body weight and muscle mass as well as
skeletal muscle dysfunction in the form of greater muscle
fatigue and reduced force output.
Skeletal muscle function in IL15TG mice in response
to E0771 mammary tumours
Based on bioinformatics analysis and our previously pub-
lished data on IL-15 in skeletal muscle, we investigated the
therapeutic efficacy of overexpressing IL-15 in a mouse
model of breast cancer on measures of muscle function. As
seen in Figure 5A and 5B, there were no differences in the
tumour growth or cell viability of E0771 tumour cells in
IL15TG mice compared with littermate controls. Additionally,
both IL15TG and littermate control mice lost a significant
amount of overall body mass (Figure 5C) and skeletal muscle
mass (Table 3) in response to tumour growth. Tumour growth
in B6 Con mice was associated with a greater rate of muscle
fatigue (Figure 5D). The AUC was significantly lower in
tumour-bearing B6 Con mice compared with non-tumour B6
Con mice (Figure 5E). Maximal isometric muscle force output
Figure 1 Skeletal muscle transcriptome in breast cancer. (A) Principle components analysis plot showing that muscle biopsies from breast cancer pa-
tients (n = 14) cluster together regardless of tumour subtype, while biopsies from non-cancer patients (n = 6) are more variable. This plot was the
rationale for analysing all breast cancer samples together instead of dividing based on the specific breast tumour subtype. (B) Normalized gene expres-
sion heat map showing the differential expression patterns of the 40 most differentially expressed genes between breast cancer patients and non-can-
cer patients. There is a down-regulation of gene expression in muscle biopsies from breast cancer patients compared with muscle from non-cancer
patients. BC, breast cancer; CON, non-cancer control.
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was significantly lower in tumour-bearing B6 Con mice
compared with non-tumour B6 Con mice (Figure 5F). There-
fore, the muscle dysfunction in response to E0771 tumour
growth was similar in both C57BL/6 wild type mice and in
B6 Con mice.
Tumour growth in IL15TG mice was associated with an
altered muscle fatigue response from that observed in B6
Con mice (Figure 5G), resulting in no significant difference
in the AUC calculated in muscles from IL15TG tumour-bearing
mice and IL15TG non-tumour mice. Furthermore, the average
AUC of muscles from IL15TG tumour-bearing mice was com-
parable with muscles from wild type non-tumour-bearing
control mice (Figure 5H). However, maximal isometric
muscle force output was significantly lower in IL15TG
tumour-bearing mice compared with IL15TG non-tumour
mice (Figure 5I). These data demonstrate that IL-15
overexpression is associated with an attenuation of the
greater muscle fatigue observed in response to E0771
mammary tumours. However, IL15TG mice were not
protected from the E0771 mammary tumour effects on over-
all body weight, skeletal muscle mass, and maximal isometric
force output.
Discussion
Inherent in the definition of cancer cachexia is the concept
of fatigue1,2 and a significant percentage of patients with
breast cancer report moderate to severe muscle fatigue.8–11
The occurrence of muscle fatigue in cancer patients is often
considered a side effect of either radiation therapy or
chemotherapy.37,38 However, fatigue can occur due to
tumour growth itself or as the result of cancer treatments.39
To the Authors’ knowledge, the skeletal muscle tran-
scriptome in response to breast cancer presented in this
manuscript is novel in this specific cancer type. Notably, we
demonstrate that canonical pathways involved with oxidative
Table 2 Dysregulated canonical pathways and associated genes in skeletal muscle biopsies from breast cancer patients
Oxidative phosphorylation and mitochondrial dysfunction
Gene Expression value P-value (adjusted)
Atp5d (ATP synthase F1 delta) 0.54 0.04
Atp13a2 (ATPase 13A2) 0.47 0.03
Cox6a1 (cytochrome c oxidase subunit 6A1) 0.89 0.03
Cox7a2 (cytochrome c oxidase subunit 7A2) 0.54 0.04
Gpx4 (glutathione peroxidase 4) 0.55 0.03
Hsd17b10 (hydroxysteroid 17-beta dehydrogenase-10) 0.53 0.005
Ndufb2 (NADH:ubiquinone oxidoreductase subunit B2) 0.40 0.04
Ndufs8 (NADH:ubiquinone oxidoreductase core subunit S8) 0.53 0.03
Sod3 (superoxide dismutase 3) 1.28 0.002
PPARα/RXRα activation and PPAR signalling
Gene Expression value P-value (adjusted)
Acvr1c (activin A receptor type 1C) 0.95 0.03
Adcy5 (adenylyl cyclase type 5) 0.94 0.01
Adipoq (adiponectin) 1.16 0.009
Fasn (fatty acid synthase) 1.04 0.02
Pparg (peroxisome proliferator-activated receptor gamma) 1.17 0.004
Prkar2b (cAMP-dependent protein kinase type II-beta) 1.21 0.006
Scand1 (SCAN domain containing protein 1) 0.57 0.02
Stat5a (signal transducer and activator of transcription 5A) 0.61 0.03
Acvr2a (activin A receptor type 2A) +0.59 0.007
Acvr2b (activin A receptor type 2B) +0.65 0.03
EP300 (histone acetyltransferase p300) +0.44 0.03
Il33 (interleukin-33) +0.44 0.03
Irs1 (insulin receptor substrate 1) +0.67 0.04
Ncoa6 (nuclear receptor coactivator 6) +0.34 0.05
Plce1 (phospholipase C epsilon 1) +0.71 0.03
Tgfb2 (transforming growth factor beta 2) +1.03 0.003
Interleukin-15 signalling and production
Gene Expression value P-value (adjusted)
Klb (klotho beta) 1.11 0.01
Stat5a (signal transducer and activator of transcription 5A) 0.61 0.03
Frs2 (fibroblast growth factor receptor substrate 2) +0.59 0.03
Gab1 (GRB2-associated binding protein 1) +0.66 0.04
Irs1 (insulin receptor substrate 1) +0.67 0.04
Prkci (protein kinase c iota) +0.57 0.02
Stat1 (signal transducer and activator of transcription 1) +0.53 0.01
ATP, adenosine triphosphate; PPAR, peroxisome proliferator-activated receptor.
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Figure 2 Canonical pathways of oxidative phosphorylation and mitochondrial dysfunction. The canonical pathways of oxidative phosphorylation and
mitochondrial dysfunction were dysregulated in the muscle samples from breast cancer patients compared with non-cancer controls. The shading pat-
tern of the individual electron transport chain complexes is used as an indicator of the degree of predicted dysfunction, with a greater percentage of
light shading suggestive of greater dysfunction. Individual genes that were significantly down-regulated are identified within the specific electron trans-
port chain complex. Specific dysregulated genes were identified using DESqe2, while the canonical pathways of oxidative phosphorylation and mito-
chondrial dysfunction were identified using Ingenuity Pathway Analysis software. ATP, adenosine triphosphate; IMM, Inner Mitochondrial Membrane.
Figure 3 Regulatory gene network upstream of beta-oxidation in mitochondria. Multiple genes involved in energy homoeostasis and mitochondrial
metabolism were down-regulated, while genes associated with muscle differentiation and stem cell function were up-regulated in muscle from breast
cancer patients. This specific gene network predicts an impairment in beta-oxidation within the mitochondria. Blue shading/arrows indicate down-reg-
ulation, and orange shading/lines indicate up-regulation.
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phosphorylation and mitochondrial dysfunction are dysregu-
lated in the skeletal muscle of breast cancer patients and
that these molecular alterations in muscle were detected
while the breast cancer was in the early stages and at a time
when patients were being treated with curative intent. The
patient population that we used in this study consisted of
eight women that did not receive any treatments prior to
surgery and biopsy acquisition (i.e. adjuvant setting) and six
women that received neoadjuvant chemotherapy prior to
surgery and biopsy acquisition. Additionally, our population
consisted of women with luminal tumours, triple positive
tumours, and triple negative tumours. Therefore, our data
suggest that skeletal muscle is quite responsive to breast tu-
mour growth and that common transcriptional alterations in
muscle occur regardless of the specific breast tumour sub-
type and whether chemotherapy has been initiated. These
data are strengthened by the fact that we observed these
alterations despite a control group that displayed consider-
able variability with respect to gene expression patterns in
muscle. Collectively, we suggest that gene networks that
regulate muscle fatigue are dysregulated in the early stages
of breast tumour growth, regardless of tumour subtype,
Figure 4 Mammary tumour-induced skeletal muscle dysfunction in wild type mice. (A) Representative live in vivo bioluminescent images of luciferase-
containing E0771 tumour cells through 4 weeks of tumour growth in the mammary fat pads of wild type mice. (B) Bioluminescent quantification of
luciferase-containing E0771 tumour cells through 4 weeks of tumour growth in the mammary fat pads of wild type mice. (C) Changes in body weight
in wild type after 4 weeks of tumour growth in the mammary fat pads of wild type mice. These weights do not include the weight of the tumour, which
was resected. (D) Differential expression of the Il15 gene in skeletal muscles of wild type mice with no tumour, and following 2 and 4 weeks of tumour
growth in the mammary fat pads. (E) Ex vivo skeletal muscle fatigue curves from wild type mice with no tumour, and following 2 and 4 weeks of tu-
mour growth in the mammary fat pads. The leftward shift of the fatigue curve in the 4WK mice is indicative of a greater rate of muscle fatigue. (F)
Quantification of the area under the fatigue curve in muscles from wild type mice with no tumour, and following 2 and 4 weeks of tumour growth
in the mammary fat pads. (G) Isometric force output at increasing stimulation frequencies in muscles from wild type mice with no tumour, and follow-
ing 2 and 4 weeks of tumour growth in the mammary fat pads. *P < 0.05; **P < 0.001; ***P < 0.0001. CON, control mice; EDL, extensor digitorum
longus; IL-15, interleukin-15.
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and that these alterations can occur prior to the onset of
muscle wasting.
The transcriptional profile in skeletal muscle in response
to breast cancer contrasts with the muscle transcriptome
associated with oesophageal, gastric, and pancreatic cancer.40
In a study by Gallagher et al.,40 patients reported an average
weight loss of 7.4% at the time of the first biopsy, which
increased to 13.8% at follow-up. The skeletal muscle tran-
scriptome in these cancer patients, which had lost body
weight, suggested a down-regulation of both anabolic and
catabolic processes that was reversed with resection of
the tumour.40 The transcriptional changes in skeletal muscle
in that particular study are, therefore, consistent with a tran-
scriptional program that supports muscle atrophy as a result
of tumour growth and is reflected in overall reductions in
body weight. One study estimated that 42% of oesophageal
cancer patients, 42% of gastric cancer patients, and 35% of
pancreatic patients experience body weight loss while only
24% of breast cancer patients experience body weight loss.5
In our sample of breast cancer patients, the average BMI at
the time of surgery and biopsy acquisition was 29.9 kg m2,
which is considered overweight.41 Although we are not able
to report whether these breast cancer patients had lost
weight, the albumin levels reported in this specific group of
breast cancer patients were within the normal range and
suggest that these patients were not experiencing any
significant nutritional deficits.42 The skeletal muscle tran-
scriptional changes in our breast cancer patients reflect
alterations in pathways that regulate skeletal muscle
fatigue, such that oxidative phosphorylation is significantly
down-regulated. In addition, PPAR signalling is down-
regulated, and this is predicted to reduce β-oxidation
within the mitochondria. Collectively, this presents the
intriguing hypothesis that cancer cachexia can take differ-
ent forms based on the specific cancer type. In cancers
associated with significant body weight and muscle mass
loss, the gene expression profile of muscle is one that
reflects pathways associated with muscle atrophy, which
would then contribute to decreased muscle strength and
force production. In contrast, in cancers associated with
greater muscle fatigue and minimal body weight or muscle
mass loss, the gene expression profile of muscle reflects
down-regulation of pathways associated with oxidative
phosphorylation, and this would be associated with muscle
dysfunction in the form of greater muscle fatigue. To
further test this hypothesis, we are in the process of
expanding our muscle biopsy collection to include RNA-
seq from Her2/neu patients and to include proteomic
analyses of muscle from breast cancer patients to present
a comprehensive molecular signature of skeletal muscle in
response to breast cancer.
Multiple genes within the mitochondrial ETC, specifically
within complexes I, IV and V, were down-regulated, which
would potentially contribute to mitochondrial dysfunction
and reduced ATP available to fuel muscle contraction.43,44
Additionally, alterations in energy metabolism through the
down-regulation of PPAR-related signalling would also con-
tribute to altered mitochondrial function.24,45,46 Collectively,
the down-regulation of mitochondrial genes as well as the
predicted down-regulation of β-oxidation through alterations
of a gene network including PPARα, PPARγ, and PGC-1α
provides a biochemical mechanism for the reported greater
fatigue experienced in breast cancer patients.8–11 Preclinical
models of cancer have supported the concept of mitochon-
drial dysfunction in response to tumour growth.47–50 In
response to Lewis lung carcinoma in mice, mitochondrial
Table 3 Muscle weights following E0771 tumour growth
E0771 tumour growth in C57BL/6 WT mice
Control (n = 8) 2WK (n = 5) 4WK (n = 10)
EDL (mg) 10.6 ± 1.2 9.9 ± 1.0 7.8 ± 1.1a, b
EDL (mg g1) 0.50 ± 0.06 0.51 ± 0.05 0.46 ± 0.05a, b
vTA (mg) 53.1 ± 6.1 48.5 ± 4.0 37.9 ± 4.7a, b
TA (mg g1) 2.7 ± 0.3 2.5 ± 0.2 2.2 ± 0.5a, b
Gastroc (mg) 114.7 ± 9.4 112.5 ± 9.9 89.5 ± 13.8a, b
Gastroc (mg g1) 5.8 ± 0.4 5.8 ± 0.6 5.3 ± 0.7a, b
E0771 tumour growth in IL15TG mice
B6 Con (n = 8) B6 Con tumour (n = 17) IL15TG (n = 7) IL15TG tumour (n = 12)
EDL (mg) 9.2 ± 1.2 8.2 ± 0.93c 8.8 ± 0.67 6.7 ± 0.63d
EDL (mg g1) 0.45 ± 0.01 0.46 ± 0.01 0.45 ± 0.01 0.38 ± 0.01d
TA (mg) 50.2 ± 1.9 41.7 ± 0.65c 46.9 ± 2.2 36.2 ± 0.68d
TA (mg g1) 2.4 ± 0.08 2.4 ± 0.04 2.4 ± 0.10 2.0 ± 0.04d
Gastroc (mg) 108.7 ± 3.4 93.9 ± 1.7c 77.3 ± 3.9 70.9 ± 2.8
Gastroc (mg g 1) 5.3 ± 0.11 5.3 ± 0.13 3.9 ± 0.18 4.0 ± 0.15
EDL, extensor digitorum longus; TA, Tibialis Anterior muscle; WT, wild type.
aControl significantly different from 4WK.
b2WK significantly different from 4WK.
cB6 Con significantly different from B6 Con tumour.
dIL15TG significantly different from IL15TG tumour.
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ATP synthesis was decreased with tumour progression.48 A
decrease in ATP production may occur through increased
uncoupling of ATP production within pathways of oxidative
phosphorylation in skeletal muscle.48,49 Exposing C2C12
myotubes to conditioned media from Lewis lung carcinoma
cells altered the function of the mitochondrial ETC
and increased mitochondrial reactive oxygen species
production.44 Therefore, tumour growth has the potential
to induce mitochondrial dysfunction, leading to reduced
ATP production within skeletal muscle and greater muscle fa-
tigue. In our preclinical study of mammary cancer, muscle
fatigue was tested ex vivo, which allows for the direct exam-
ination of fatigue in response to muscle contractions without
confounding effects of alterations in muscle blood flow,
oxygenation, or temperature that could contribute to altered
fatigue in vivo. The EDL muscle was significantly more
fatigable following 4 weeks of mammary tumour growth
compared with muscles from control mice and following
2 weeks of tumour growth. Notably, the shape of the fatigue
curve in muscles following 4 weeks of tumour growth,
especially during the first 70 s of the fatigue protocol, was
significantly different and dropped sharply in response to
Figure 5 Skeletal muscle function in IL15TG mice following mammary tumour growth. (A) Representative live in vivo bioluminescent images of
luciferase-containing E0771 tumour cells after 4 weeks of tumour growth in the mammary fat pads of B6 littermate control and IL15TG mice.
(B) Bioluminescent quantification of luciferase-containing E0771 tumour cells through 4 weeks of tumour growth in the mammary fat pads of
B6 littermate control and IL15TG mice. (C) Changes in body weight in wild type after 4 weeks of tumour growth in the mammary fat pads of
wild type mice. These weights do not include the weight of the tumour, which was resected. (D) Ex vivo skeletal muscle fatigue curves from
B6 littermate control mice with no tumour, and following 4 weeks of tumour growth in the mammary fat pads. The leftward shift of the fatigue
curve in the CON tumour mice is indicative of a greater rate of muscle fatigue. (E) Quantification of the area under the fatigue curve in muscles
from B6 littermate control mice with no tumour, and following 4 weeks of tumour growth in the mammary fat pads. (F) Isometric force output at
increasing stimulation frequencies in muscles from B6 littermate control mice with no tumour, and following 4 weeks of tumour growth in the
mammary fat pads. (G) Ex vivo skeletal muscle fatigue curves from IL15TG mice with no tumour, and following 4 weeks of tumour growth in
the mammary fat pads. (H) Quantification of the area under the fatigue curve in muscles from IL15TG mice with no tumour, and following 4 weeks
of tumour growth in the mammary fat pads. (F) Isometric force output at increasing stimulation frequencies in muscles from IL15TG mice with no
tumour, and following 4 weeks of tumour growth in the mammary fat pads. In Figures C, E, and F, solid lines represent the average value from
wild type non-tumour-bearing mice, and dotted lines represent the average value from wild type mice following 4 weeks of tumour growth.
*P < 0.05; **P < 0.001; ***P < 0.0001. EDL, extensor digitorum longus.
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muscle contractions. These data suggest that mammary
tumour growth induces muscle fatigue that is directly
due to alterations within the muscle itself, providing a func-
tional outcome for the cellular mechanisms previously
identified.44,47–49
In the current study, skeletal muscle il15 gene expression
was lower in tumour-bearing wild type mice, especially
after 4 weeks of tumour growth. Our laboratory,18,19 and
others,20,21 have presented data to support the hypothesis
that greater IL-15 is associated with increased mitochondrial
density in skeletal muscle and, therefore, a greater oxidative
capacity of skeletal muscle. We tested this mechanism in our
mouse model of breast cancer using muscle-specific IL-15
overexpressing transgenic mice and demonstrated that
muscle force output with repeated contractions (i.e. fatigue)
is spared in these mice following mammary tumour growth.
Specifically, EDL muscles from IL15TG mice following 4 weeks
of mammary tumour growth produced more aggregate force
during the fatigue protocol when compared with non-tu-
mour-bearing wild type control and littermate control mice.
The AUC calculated from the fatigue curves of muscles from
IL15TG mice following 4 weeks of tumour growth was similar
to AUC from control non-tumour-bearing mice. In a prior
study, IL15TG mice had greater times to exhaustion during a
treadmill test and increased molecular markers consistent
with changes in oxidative capacity of muscle.20 Additionally,
muscles from IL15RαKO mice, which also have a greater
circulating level of IL-15, were resistant to ex vivo induced
muscle fatigue.18 Data in muscle cells and in transgenic
mice support the ability of IL-15 to enhance the expression
of multiple regulators of mitochondrial biogenesis, including
PPARδ, PPARβ, and PGC-1α,19,20,24 which we found to be
down-regulated in breast cancer patients. These data
support the notion that elevating IL-15 levels within the
muscle and in the circulation can enhance the oxidative
capacity of skeletal muscle, which can be used as a therapeu-
tic strategy to attenuate fatigue in response to breast tumour
growth. Additional studies are in progress in our laboratory
to move from the use of genetically modified mice and
determine proper dosing in vivo of IL-15 for these muscle-
specific effects.
In summary, our data support the hypothesis that breast
cancer patients are susceptible to greater muscle fatigue
due to molecular alterations within skeletal muscle, which
occurred regardless of breast tumour subtype or whether
chemotherapy was initiated prior to biopsy collection.
Furthermore, these molecular alterations in muscle were
detected while the breast cancer was at its earliest stage,
and patients were being treated with curative intent. Two
prediction algorithms suggested a dysregulation of the
canonical pathways involved in oxidative phosphorylation,
mitochondrial dysfunction, and PPAR signalling and activa-
tion. Because these muscle-specific transcriptional changes
in response to breast cancer differ from those reported in
patients with oesophageal, gastric, and pancreatic cancers
that had lost weight,40 we suggest that skeletal muscle
responses to cancer can differ between cancer types, and this
would be associated with different functional outcomes in
skeletal muscle. In cancer patients that have lost significant
amounts of body weight and/or muscle mass, pathways in
skeletal muscle would promote muscle atrophy and alter-
ations in protein turnover, which would predispose these
patients to lower strength levels.40 In contrast, in patients
that do not experience significant body weight or muscle
mass loss, pathways in skeletal muscle could promote alter-
ations in mitochondrial function, which would predispose
these patients to greater muscle fatigue.4 Bioinformatics
analysis also suggested a dysregulation of IL-15 signalling
and activation in muscle of breast cancer patients, and
il15 gene expression was lower in muscles from our mouse
model of mammary cancer. Skeletal muscle overexpression
of IL-15, and subsequent secretion into the circulation,
attenuated muscle fatigue in response to mammary tumour
growth in mice, suggesting that IL-15-based therapies
may be useful to counter breast cancer-associated muscle
fatigue. Therefore, we propose that skeletal muscle fatigue
is an inherent consequence of breast tumour growth,
which can manifest in early stage disease without signifi-
cant loss of body weight or muscle mass, and has the
potential to be targeted therapeutically, as our preclinical
data suggest.
Acknowledgements
The authors certify that they comply with the ethical
guidelines for authorship and publishing of the Journal of
Cachexia, Sarcopenia and Muscle.51
The Authors thank Jessica Partin, MD, and Christin Ueno,
MD, for assistance with acquisition of muscle biopsies; Linda
Metheny-Barlow, PhD, for providing the E0771 tumour cells
for this project; and Kevin Fox, MD, and Hannah E. Wilson
for thoughtful critique of the manuscript.
This research was supported by grants from the American
Cancer Society (IRG: 09-061-04) and WVCTSI through the
National Institute of General Medical Sciences of the National
Institutes of Health (U54GM104942) awarded to E.P.
Additional support for this research was provided by the
Animal Models and Imaging Core Facility (S10RR026378 and
U54GM104942) and West Virginia IDeA Biomedical Research
Excellence (WV-INBRE) (P20GM103434).
Conflict of interest
All Authors of this manuscript (J.B., S.M., H.H., A.I., C.M., M.
D., and E.P.) declare no conflicts of interest.
712 J. Bohlen et al.
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 701–714
DOI: 10.1002/jcsm.12294
References
1. Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, et al. Definition
and classification of cancer cachexia: an in-
ternational consensus. Lancet Oncol 2011;
12:489–495.
2. Evans WJ, Morley JE, Argiles J, Bales C,
Baracos V, Guttridge D, et al. Cachexia: a
new definition. Clin Nutr 2008;27:793–799.
3. Evans WJ, Lambert CP. Physiological basis
of fatigue. Am J Phys Med Rehabil
2007;86:S29–S46.
4. Neefjes ECW, van den Hurk RM, Blauwhoff-
Buskermolen S, van der Vorst M, Becker-
Commissaris A, de van der Schueren MAE,
et al. Muscle mass as a target to reduce fa-
tigue in patients with advanced cancer. J Ca-
chexia Sarcopenia Muscle 2017;8:623–629.
5. Fox KM, Brooks JM, Gandra SR, Markus R,
Chiou CF. Estimation of cachexia among
cancer patients based on four definitions. J
Oncol 2009;2009:693458.
6. Klassen O, Schmidt ME, Ulrich CM,
Schneeweiss A, Potthoff K, Steindorf K,
et al. Muscle strength in breast cancer pa-
tients receiving different treatment re-
gimes. J Cachexia Sarcopenia Muscle
2017;8:305–316.
7. Neil-Sztramko SE, Kirkham AA, Hung SH,
Niksirat N, Nishikawa K, Campbell KL. Aero-
bic capacity and upper limb strength are
reduced in women diagnosed with breast
cancer: a systematic review. J Physiother
2014;60:189–200.
8. Bower JE, Ganz PA, Desmond KA, Rowland
JH, Meyerowitz BE, Belin TR. Fatigue in
breast cancer survivors: occurrence, corre-
lates, and impact on quality of life. J Clin
Oncol 2000;18:743–753.
9. Cella D, Lai JS, Chang CH, Peterman A, Slavin
M. Fatigue in cancer patients compared with
fatigue in the general United States popula-
tion. Cancer 2002;94:528–538.
10. Curt GA, Breitbart W, Cella D, Groopman
JE, Horning SJ, Itri LM, et al. Impact of
cancer-related fatigue on the lives of
patients: new findings from the Fatigue
Coalition. Oncologist 2000;5:353–360.
11. Blesch KS, Paice JA, Wickham R, Harte N,
Schnoor DK, Purl S, et al. Correlates of fa-
tigue in people with breast or lung cancer.
Oncol Nurs Forum 1991;18:81–87.
12. Powers SK, Lynch GS, Murphy KT, Reid MB,
Zijdewind I. Disease-induced skeletal mus-
cle atrophy and fatigue. Med Sci Sports
Exerc 2016;48:2307–2319.
13. Mustian KM, Peppone L, Darling TV, Palesh
O, Heckler CE, Morrow GR. A 4-week
home-based aerobic and resistance exer-
cise program during radiation therapy: a
pilot randomized clinical trial. J Support
Oncol 2009;7:158–167.
14. Courneya KS, Segal RJ, Mackey JR, Gelmon
K, Reid RD, Friedenreich CM, et al. Effects
of aerobic and resistance exercise in breast
cancer patients receiving adjuvant chemo-
therapy: a multicenter randomized con-
trolled trial. J Clin Oncol 2007;25:
4396–4404.
15. Conlon KC, Lugli E, Welles HC, Rosenberg
SA, Fojo AT, Morris JC, et al. Redistribution,
hyperproliferation, activation of natural
killer cells and CD8 T cells, and cytokine
production during first-in-human clinical
trial of recombinant human interleukin-15
in patients with cancer. J Clin Oncol
2015;33:74–82.
16. Waldmann TA, Tagaya Y. The multifaceted
regulation of interleukin-15 expression
and the role of this cytokine in NK cell
differentiation and host response to intra-
cellular pathogens. Annu Rev Immunol
1999;17:19–49.
17. Fehniger TA, Caligiuri MA. Interleukin 15:
biology and relevance to human disease.
Blood 2001;97:14–32.
18. Pistilli EE, Bogdanovich S, Garton F, Yang N,
Gulbin JP, Conner JD, et al. Loss of IL-15 re-
ceptor alpha alters the endurance, fatiga-
bility, and metabolic characteristics of
mouse fast skeletal muscles. J Clin Invest
2011;121:3120–3132.
19. O’Connell GC, Pistilli EE. Interleukin-15
directly stimulates pro-oxidative gene
expression in skeletal muscle in-vitro via a
mechanism that requires interleukin-15
receptor alpha. Biochem Biophys Res
Commun 2015;458:614–619.
20. Quinn LS, Anderson BG, Conner JD,
Wolden-Hanson T. IL-15 overexpression
promotes endurance, oxidative energy me-
tabolism, and muscle PPARdelta, SIRT1,
PGC-1alpha, and PGC-1beta expression in
male mice. Endocrinology 2013;154:
232–245.
21. Quinn LS, Anderson BG, Conner JD,
Wolden-Hanson T, Marcell TJ. IL-15 is re-
quired for postexercise induction of the
pro-oxidative mediators PPARdelta and
SIRT1 in male mice. Endocrinology
2014;155:143–155.
22. Pistilli EE, Quinn LS. From anabolic to
oxidative: reconsidering the roles of IL-15
and IL-15Ralpha in skeletal muscle. Exerc
Sport Sci Rev 2013;41:100–106.
23. O’Connell G, Guo G, Stricker J, Quinn LS,
Ma A, Pistilli EE. Muscle-specific deletion
of exons 2 and 3 of the IL15RA gene in
mice: effects on contractile properties of
fast and slow muscles. J Appl Physiol
1985;118:437–448.
24. Thornton SM, Krolopp JE, Abbott MJ. IL-15
mediates mitochondrial activity through a
PPARdelta-dependent-PPARalpha-
independent mechanism in skeletal muscle
cells. PPAR Res 2016;2016:5465804.
https://doi.org/10.1155/2016/5465804
25. Pistilli EE, Jackson JR, Alway SE. Death
receptor-associated pro-apoptotic signal-
ing in aged skeletal muscle. Apoptosis
2006;11:2115–2126.
26. Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, et al. STAR: ultrafast uni-
versal RNA-seq aligner. Bioinformatics
2013;29:15–21.
27. Liao Y, Smyth GK, Shi W. featureCounts: an
efficient general purpose program for
assigning sequence reads to genomic fea-
tures. Bioinformatics 2014;30:923–930.
28. Anders S, Huber W. Differential expression
analysis for sequence count data. Genome
Biol 2010;11:R106.
29. Luo W, Friedman MS, Shedden K,
Hankenson KD, Woolf PJ. GAGE: generally
applicable gene set enrichment for path-
way analysis. BMC Bioinformatics
2009;10:161.
30. Quinn LS, Anderson BG, Strait-Bodey L,
Stroud AM, Argiles JM. Oversecretion of
interleukin-15 from skeletal muscle re-
duces adiposity. Am J Physiol Endocrinol
Metab 2009;296:E191–E202.
31. Ewens A, Mihich E, Ehrke MJ. Distant me-
tastasis from subcutaneously grown
E0771 medullary breast adenocarcinoma.
Anticancer Res 2005;25:3905–3915.
32. Carrasco E, Alvarez PJ, Melguizo C, Prados
J, Alvarez-Manzaneda E, Chahboun R,
et al. Novel merosesquiterpene exerts a
potent antitumor activity against breast
cancer cells in vitro and in vivo. Eur J Med
Chem 2014;79:1–12.
33. Sugiura K, Stock CC. Studies in a tumor
spectrum. I. Comparison of the action of
methylbis (2-chloroethyl)amine and 3-
bis(2-chloroethyl)aminomethyl-4-
methoxymethyl-5-hydroxy-6-
methylpyridine on the growth of a variety
of mouse and rat tumors. Cancer
1952;5:382–402.
34. O’Connell G, Guo G, Stricker J, Quinn LS,
Ma A, Pistilli EE. Muscle-specific deletion
of exons 2 and 3 of the IL15RA gene in
mice: effects on contractile properties of
fast and slow muscles. J Appl Physiol
(1985) 2015;118:437–448.
35. Pistilli EE, Alway SE, Hollander JM,
Wimsatt JH. Aging alters contractile prop-
erties and fiber morphology in pigeon
skeletal muscle. J Comp Physiol B
2014;184:1031–1039.
36. Burke RE, Levine DN, Tsairis P, Zajac FE
3rd. Physiological types and histochemi-
cal profiles in motor units of the cat
gastrocnemius. J Physiol 1973;234:
723–748.
37. Irvine D, Vincent L, Graydon JE, Bubela N,
Thompson L. The prevalence and correlates
of fatigue in patients receiving treatment
with chemotherapy and radiotherapy. A
comparison with the fatigue experienced
by healthy individuals. Cancer Nurs 1994;
17:367–378.
38. Irvine DM, Vincent L, Graydon JE, Bubela N.
Fatigue in women with breast cancer re-
ceiving radiation therapy. Cancer Nurs
1998;21:127–135.
39. Hofman M, Ryan JL, Figueroa-Moseley CD,
Jean-Pierre P, Morrow GR. Cancer-related
fatigue: the scale of the problem. Oncolo-
gist 2007;12:4–10.
40. Gallagher IJ, Stephens NA, MacDonald AJ,
Skipworth RJ, Husi H, Greig CA, et al. Suppres-
sion of skeletal muscle turnover in cancer ca-
chexia: evidence from the transcriptome in
Skeletal muscle transcriptome of breast cancer patients 713
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 701–714
DOI: 10.1002/jcsm.12294
sequential human muscle biopsies. Clin Can-
cer Res 2012;18:2817–2827.
41. Parr RB, Obesity. In Ehrman JK, Gordon PM,
Visich PS, Keteyian SJ, eds. Clinical Exercise
Physiology. Champaign, Illinois: Human
Kinetics; 2003. p153–167.
42. Gupta D, Lis CG. Pretreatment serum albu-
min as a predictor of cancer survival: a sys-
tematic review of the epidemiological
literature. Nutr J 2010;9.
43. Zielinski LP, Smith AC, Smith AG, Robinson
AJ. Metabolic flexibility of mitochondrial
respiratory chain disorders predicted by
computer modelling. Mitochondrion
2016;31:45–55.
44. McLean JB, Moylan JS, Andrade FH.
Mitochondria dysfunction in lung cancer-
induced muscle wasting in C2C12
myotubes. Front Physiol 2014;5.
45. Fan W, Evans R. PPARs and ERRs: molecu-
lar mediators of mitochondrial metabo-
lism. Curr Opin Cell Biol 2015;33:49–54.
46. Dressel U, Allen TL, Pippal JB, Rohde PR,
Lau P, Muscat GE. The peroxisome
proliferator-activated receptor beta/delta
agonist, GW501516, regulates the expres-
sion of genes involved in lipid catabolism
and energy uncoupling in skeletal muscle
cells. Mol Endocrinol 2003;17:2477–2493.
47. Tzika AA, Fontes-Oliveira CC, Shestov AA,
Constantinou C, Psychogios N, Righi V,
et al. Skeletal muscle mitochondrial
uncoupling in a murine cancer cachexia
model. Int J Oncol 2013;43:886–894.
48. Constantinou C, Fontes de Oliveira CC,
Mintzopoulos D, Busquets S, He J,
Kesarwani M, et al. Nuclear magnetic reso-
nance in conjunction with functional
genomics suggests mitochondrial dysfunc-
tion in a murine model of cancer cachexia.
Int J Mol Med 2011;27:15–24.
49. Collins P, Bing C, McCulloch P, Williams G.
Muscle UCP-3 mRNA levels are elevated
in weight loss associated with gastrointesti-
nal adenocarcinoma in humans. Br J Cancer
2002;86:372–375.
50. Carson JA, Hardee JP, VanderVeen BN. The
emerging role of skeletal muscle oxidative
metabolism as a biological target and
cellular regulator of cancer-induced muscle
wasting. Semin Cell Dev Biol 2016;54:
53–67.
51. von Haehling S, Morley JE, Coats AJS, Anker
SD. Ethical guidelines for publishing in the
Journal of Cachexia, Sarcopenia and Mus-
cle: update 2017. J Cachexia Sarcopenia
Muscle 2017;8:1081–1083.
714 J. Bohlen et al.
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 701–714
DOI: 10.1002/jcsm.12294
